TROP2 methylation and expression in tamoxifen-resistant breast cancer

TROP2 methylation and expression in tamoxifen-resistant breast cancer

Abstract Background The DNA methyltransferase 1 inhibitor, 5-Aza-2′-deoxycytidine (5-Aza-dC) is a potential treatment for breast cancer. However, not all breast tumors will respond similarly to treatment with 5-Aza-dC, and little is known regarding the response of hormone-resistant breast cancers to...

Full description

Bibliographic Details
Main Authors: Stephanie M. Zimmers, Eva P. Browne, Kristin E. Williams, Rahul M. Jawale, Christopher N. Otis, Sallie S. Schneider, Kathleen F. Arcaro
Format: Article
Language:English
Published: BMC 2018-07-01
Series:Cancer Cell International
Subjects:
TROP2
DNA methylation
Tamoxifen-resistant breast cancer (or Tamoxifen resistance breast cancer)
TACSTD2
Human Methylation 450 BeadChip
5-aza-2′-deoxycytidine (or decitabine or 5-Aza-dC)
Online Access:http://link.springer.com/article/10.1186/s12935-018-0589-9

Internet

http://link.springer.com/article/10.1186/s12935-018-0589-9

Similar Items